Results 101 to 110 of about 491,152 (275)

Antimicrobial Drug Consumption on Swiss Pig Farms: A Comparison of Swiss and European Defined Daily and Course Doses in the Field

Frontiers in Veterinary Science, 2019
Defined Daily Doses (DDD) and Defined Course Doses (DCD) have been established in both human and veterinary medicine in order to standardize the measurement of treatments in a population.
Thomas Echtermann, Cedric Muentener, Xaver Sidler, Dolf Kümmerlen   +3 more
doaj   +1 more source

Developmental programmes drive cellular plasticity, disease progression and therapy resistance in lung adenocarcinoma

Molecular Oncology, EarlyView.
This study shows that lung adenocarcinomas exploit developmental branching morphogenesis to acquire a therapy resistant basal‐like tumour cell state. This process was found to be regulated by combined TP53 loss‐of‐function and type‐I interferon signalling, identifying a novel axis for biomarker and therapeutic target discovery.
Kamila J Bienkowska, Stephany Gallardo, Nur S. Zainal, Leena Arora, Matthew Ellis, Maria‐Antoinette Lopez, Judith Austine, Sai Pittla, Serena J Chee, Aiman Alzetani, Emily C Shaw, Christian H Ottensmeier, Gareth J Thomas, Christopher J Hanley   +13 more
wiley   +1 more source

Stimulator of interferon genes agonist augmented antitumor immunity of osimertinib in Egfr‐mutated lung cancer

Molecular Oncology, EarlyView.
Combining osimertinib with the STING agonist ADU‐S100 activates innate and adaptive immunity to overcome the non‐inflamed microenvironment of Egfr‐mutant lung cancer. This combination increases NK and CD8+ T‐cell infiltration, associated with activation of the STING‐IRF3 pathway and local immunogenic cell death.
Jun Nishimura, Tadahiro Kuribayashi, Johannes Brägelmann, Sachi Okawa, Masataka Taoka, Shunta Mori, Tomoka Nishimura, Takaaki Tanaka, Go Makimoto, Kiichiro Ninomiya, Kammei Rai, Eiki Ichihara, Ryohei Katayama, Katsuyuki Hotta, Masahiro Tabata, Yosuke Togashi, Yoshinobu Maeda, Martin L. Sos, Katsuyuki Kiura, Kadoaki Ohashi   +19 more
wiley   +1 more source

Influence of the frequency at which the doctors accepted gifts on the number of prescriptions, the daily doses (defined daily dose, DDD) and expenditure per patient (means +/− SD).

, 2014
The p-values result from two-sided tests comparing the means reported above and below. Differences nominally significant at a level of p≤0.005 (see methods) are reported with a bold font p-value.Influence of the frequency at which the doctors accepted ...
Klaus Lieb (304103), Armin Scheurich (512454)   +1 more
core   +1 more source

Loss of IGF‐1R impairs DNA‐PKcs recruitment to chromatin leading to defective end‐joining

Molecular Oncology, EarlyView.
IGF‐1R promotes radioresistance by facilitating DNA‐PKcs recruitment to chromatin, enabling non‐homologous end‐joining (NHEJ) repair of double‐strand breaks. Inhibition or loss of IGF‐1R disrupts this recruitment to damage sites, driving compensatory reliance on microhomology‐mediated end‐joining (MMEJ) repair.
Matthew O. Ellis, Jack V. Mills, Wojciech Niedzwiedz, Valentine M. Macaulay   +3 more
wiley   +1 more source

Trends of carbapenem-resistant Acinetobacter baumannii isolates (%) and carbapenem use (AUD, defined daily dose per 1,000 patient-days) during the study period.

, 2014
Trends of carbapenem-resistant Acinetobacter baumannii isolates (%) and carbapenem use (AUD, defined daily dose per 1,000 patient-days) during the study period.
Seung Eun Lee (314141), Young Kyung Yoon (575025), Hyun Jeong Kim (418535), Jang Wook Sohn (575027), Min Ja Kim (575028), Kyung Sook Yang (575026)   +5 more
core   +1 more source

Longitudinal genome‐wide aneuploidy measurements in circulating cell‐free DNA to predict lack of benefit from pembrolizumab in patients with metastatic urothelial cancer

Molecular Oncology, EarlyView.
Many patients with urothelial cancer do not benefit from treatment with pembrolizumab, while at risk of severe side effects. Changes in the levels of circulating tumor DNA early during treatment, measured by a simple and affordable assay that can be easily implemented in the clinic, can be used as a prognostic tool to identify these patients.
Youssra Salhi, Stavros Makrodimitris, Sandra van Wilpe, Iris te Paske, Vanja de Weerd, Corine M. Beaufort, Hans M. Westgeest, Jens Voortman, Maureen J. B. Aarts, Maud Rijnders, Astrid A. M. van der Veldt, Ronald de Wit, Niven Mehra, Saskia M. Wilting, Debbie G. J. Robbrecht   +14 more
wiley   +1 more source

Average treatment incidences (min-max) based on animal defined daily dose (ADD; TI_ADD) and used dose (UDD; TI_PDD) of the parenteral antimicrobial drugs in the three different herd types.

, 2016
Average treatment incidences (min-max) based on animal defined daily dose (ADD; TIADD) and used dose (UDD; TIPDD) of the parenteral antimicrobial drugs in the three different herd types.
Benedicte Callens (2179862), Jeroen Dewulf (2179868), Freddy Haesebrouck (149708), Geert Opsomer (2179872), Dominiek Maes (2179870), Aart de Kruif (2179874), Bart Pardon (2179864), Mia Vanrobaeys (2179866), Boudewijn Catry (416579)   +8 more
core   +1 more source

Evaluation of Candida bloodstream infection and antifungal utilization in a tertiary care hospital

BMC Infectious Diseases, 2018
Background Candida bloodstream infections carry a significant mortality risk, justifying the importance of adequate antifungal therapy. This study describes trends in antifungal consumption using the Defined Daily Dose (DDD) and Days of Therapy (DOT ...
Tatiana Aporta Marins, Alexandre R. Marra, Michael B. Edmond, Marines Dalla Valle Martino, Paula Kiyomi Onaga Yokota, Ana Carolina Cintra Nunes Mafra, Marcelino Souza Durão Junior   +6 more
doaj   +1 more source

Patient therapy outcome modeling in cancer organoids is improved by cancer‐associated fibroblasts and organoid assembly convolution

Molecular Oncology, EarlyView.
Patient‐derived organoids (PDOs) from pancreatic, colorectal, and gastric cancers were used to evaluate standard and experimental therapies. Incorporating cancer‐associated fibroblasts (CAFs) into organoid cultures improved patient therapy outcome prediction.
Marcin Grochowski, Liudmyla Dolinchuk, Michał Jerzak, Albert Gandurski, Tomasz Grochowski, Weronika Wojtyś, Maciej Zadrożny, Wojciech Kaźmierczak, Małgorzata Lenarcik, Marta Matejak‐Górska, Radosław Samsel, Tomasz Olesiński, Dawid Walerych   +12 more
wiley   +1 more source